A new cancer treatment has shown promise in late-stage trials. This treatment is tailored to individual patients with melanoma, a serious form of skin cancer. It combines an existing immunotherapy drug with a customized therapy designed to target the unique characteristics of each patient's tumor.

The therapy is created by analyzing the tumor after surgery and identifying its specific mutations. Further details about the treatment and trial results are expected to be shared at upcoming medical meetings and with regulators.

Full results from the trial have not been disclosed, but the companies involved have announced a major advance in testing this personalized cancer treatment.